# First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody)

Source: https://onco.cc/trials/nct03852511/  
OnCo record `nct03852511` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of NG-350A run by Akamis Bio, completed.

## Summary

First in Human Study of NG-350A (an Oncolytic Adenoviral Vector Which Expresses an Anti-CD40 Antibody) is a phase 1 interventional study registered as NCT03852511 by Akamis Bio, with 28 participants enrolled, started 2019-02-19, primary completion reached 2022-02-04. Conditions recorded: Metastatic Cancer, Epithelial Tumor. Interventions recorded: NG-350A.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT03852511
- Phase: 1
- Setting: A Multicentre, Open Label, Non-randomised First in Human Study of NG-350A (Monotherapy), and NG-350A With a Check Point Inhibitor in Patients With Metastatic or Advanced Epithelial Tumours
- Sponsor: Akamis Bio
- Enrolled: 28

## Sources

- ClinicalTrials.gov NCT03852511: https://clinicaltrials.gov/study/NCT03852511

## Connected records

- drugs: [NG-350A](https://onco.cc/drugs/ng-350a/)
- companies: [Akamis Bio](https://onco.cc/companies/akamis-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct03852511.json